Back to top
more

Ligand Pharmaceuticals (LGND)

(Real Time Quote from BATS)

$90.90 USD

90.90
37,017

+4.02 (4.63%)

Updated Jul 9, 2024 11:17 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ligand (LGND) Down 4.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks.com featured highlights include Ligand Pharmaceuticals, Alarm.com Holdings, Radius Global, ADT, Madison Square Garden

by Zacks Equity Research

Ligand Pharmaceuticals, Alarm.com Holdings, Radius Global, ADT, Madison Square Garden are part of Zacks Screen of the Week article.

Rimmi Singhi headshot

Spot the Red Flags & Sell These 5 Toxic Stocks Right Away

by Rimmi Singhi

Detoxify your holdings by steering clear of these five stocks, Alarm.com (ALRM), Ligand (LGND), Radius Global (RADI), ADT Inc. (ADT) and Madison Square (MSGE).

Zacks.com featured highlights include Madison Square Garden Entertainment, Materialise, InnovAge Holding, and Ligand Pharmaceuticals

by Zacks Equity Research

Madison Square Garden Entertainment, Materialise, InnovAge Holding, and Ligand Pharmaceuticals are part of zacks screen of the week article.

Rimmi Singhi headshot

Detoxify Your Holdings by Steering Clear of These 4 Stocks

by Rimmi Singhi

Getting rid of fundamentally weak toxic stocks is important to shield your portfolio from losses. MSGE, MTLS, INNV and LGND are a few toxic stocks according to our model that you should dump now.

Ligand (LGND) Q1 Earnings Beat, OmniAb Spin-Off on Track

by Zacks Equity Research

Ligand (LGND) reports encouraging first-quarter 2022 numbers by beating estimates on both counts. However, Captisol sales get hurt by lower demand for COVID-19 therapies.

Ligand Pharmaceuticals (LGND) Q1 Earnings Lag Estimates

by Zacks Equity Research

Ligand (LGND) delivered earnings and revenue surprises of -4.92% and 33.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks.com featured highlights Ligand Pharmaceuticals, Las Vegas Sands, CoStar Group and Blackbaud

by Zacks Equity Research

Ligand Pharmaceuticals, Las Vegas Sands, CoStar Group and Blackbaud have been highlighted in this Screen of the Week article.

Rimmi Singhi headshot

Don't Let These Toxic Stocks Disrupt Your Portfolio

by Rimmi Singhi

Ligand (LGND), Las Vegas Sands (LVS), CoStar (CSGP) and Blackbaud (BLKB) are a few toxic stocks that you should dump to avoid portfolio bleeding.

Ligand (LGND) Inks Merger Deal With SPAC for OmniAb Spin-Off

by Zacks Equity Research

Ligand (LGND) is on track to spin-off its OmniAb business in the second half of 2022. It signs a merger agreement with a special purpose acquisition company (SPAC), Avista Public Acquisition Corp. for the same.

Ligand (LGND) Q4 Earnings Beat, OmniAb Spin-Off in 1H22

by Zacks Equity Research

Ligand (LGND) reports encouraging fourth-quarter 2021 numbers by beating estimates on both counts. However, royalties decline. The company plans to complete business separation in the first half of 2022.

Indrajit Bandyopadhyay headshot

Medical Stocks' Q4 Earnings on Feb 17: RGEN, IRWD & More

by Indrajit Bandyopadhyay

Let us take a look at four biotech or drug companies - RGEN, IRWD, EXEL and LGND - due to release their quarterly results on Feb 16.

Viking (VKTX) Study on X-ALD Put on Clinical Hold by the FDA

by Zacks Equity Research

Viking (VKTX) phase Ib study on VK0214 in patients with X-ALD put on hold by the FDA.

Absci (ABSI) Inks Research Agreement With Merck, Stock Up

by Zacks Equity Research

Absci (ABSI) signs a deal with Merck for using its AI-powered drug creation platform to produce enzymes for Merck's biomanufacturing applications with an option for the development of three novel drugs.

    Ligand (LGND) Stock Surges 60% YTD: What's Driving the Rally?

    by Zacks Equity Research

    Strong demand for two of Ligand's (LGND) partnered drugs, AMGN's Krprolis and GILD's Veklury, is driving its royalties. This is likely to continue next year.

    Ligand (LGND) Moves 4.5% Higher: Will This Strength Last?

    by Zacks Equity Research

    Ligand (LGND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

    Ligand's (LGND) Drug-Developing Technologies Holds Potential

    by Zacks Equity Research

    Ligand's (LGND) Captisol technology is a key driver for its topline. The company plans to spin off another potential technology platform, OmniAb, into a separate company.

    Ligand (LGND) Beats on Q3 Earnings, Plans to Separate OmniAb

    by Zacks Equity Research

    Ligand (LGND) reports encouraging third-quarter 2021 numbers by beating estimates on both counts.

    Ligand Pharmaceuticals (LGND) Beats Q3 Earnings and Revenue Estimates

    by Zacks Equity Research

    Ligand (LGND) delivered earnings and revenue surprises of 54.90% and 7.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

    Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    New Strong Sell Stocks for August 5th

    by Zacks Equity Research

    AZRX, GHL, HEES, LGND, and POLY have been added to the Zacks Rank #5 (Strong Sell) List on August 5, 2021.

    Ligand (LGND) Q2 Earnings & Sales Beat, 2021 Guidance Cut

    by Zacks Equity Research

    Ligand (LGND) reports encouraging second-quarter 2021 numbers by beating estimates on both counts.

    Ligand Pharmaceuticals (LGND) Q2 Earnings and Revenues Top Estimates

    by Zacks Equity Research

    Ligand (LGND) delivered earnings and revenue surprises of 12.41% and 15.49%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

    Ligand Pharmaceuticals (LGND) Earnings Expected to Grow: Should You Buy?

    by Zacks Equity Research

    Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Ligand (LGND) Moves 3.1% Higher: Will This Strength Last?

    by Zacks Equity Research

    Ligand (LGND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.